New Therapies for Psoriasis

被引：5
作者：
Strober, Bruce E. [1 ]
机构：
[1] Univ Connecticut, Ctr Hlth, Dept Dermatol, Farmington, CT USA
来源：
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY | 2016年 / 35卷
关键词：
Apremilast; efficacy; psoriasis; safety; secukinumab; PHOSPHODIESTERASE-4; INHIBITOR; PLAQUE PSORIASIS; PHASE-III; APREMILAST; MODERATE;
D O I：
10.12788/j.sder.2016.020
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Among the newer medications for treating psoriasis are the interleukin-17A inhibitor secukinumab and the phosphodiesterase 4 inhibitor apremilast. Secukinumab offers a level of efficacy greater than that of the tumor necrosis factor-alpha inhibitor adalimumab. Apremilast is associated with lower levels of efficacy than the biologic therapies for psoriasis. Apremilast may cause diarrhea and nausea and is associated with weight loss and rare instances of depression. (C) 2016 published by Frontline Medical Communications
引用
收藏
页码：S71 / S73
页数：3
相关论文
共 12 条
  • [1] [Anonymous], 2015, OT PACK INS
  • [2] [Anonymous], 2016, COS PACK INS
  • [3] Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
    Hueber, Wolfgang
    Sands, Bruce E.
    Lewitzky, Steve
    Vandemeulebroecke, Marc
    Reinisch, Walter
    Higgins, Peter D. R.
    Wehkamp, Jan
    Feagan, Brian G.
    Yao, Michael D.
    Karczewski, Marek
    Karczewski, Jacek
    Pezous, Nicole
    Bek, Stephan
    Bruin, Gerard
    Mellgard, Bjoern
    Berger, Claudia
    Londei, Marco
    Bertolino, Arthur P.
    Tougas, Gervais
    Travis, Simon P. L.
    [J]. GUT, 2012, 61 (12) : 1693 - 1700
  • [4] Korman NJ, 2015, 73 ANN M AM AC DERM
  • [5] Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
    Langley, Richard G.
    Elewski, Boni E.
    Lebwohl, Mark
    Reich, Kristian
    Griffiths, Christopher E. M.
    Papp, Kim
    Puig, Lluis
    Nakagawa, Hidemi
    Spelman, Lynda
    Sigurgeirsson, Bardur
    Rivas, Enrique
    Tsai, Tsen-Fang
    Wasel, Norman
    Tyring, Stephen
    Salko, Thomas
    Hampele, Isabelle
    Notter, Marianne
    Karpov, Alexander
    Helou, Silvia
    Papavassilis, Charis
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (04) : 326 - 338
  • [6] Menter A, 2014, 23 EUR AC DERM VEN C
  • [7] Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    Menter, Alan
    Tyring, Stephen K.
    Gordon, Kenneth
    Kimball, Alexa B.
    Leonardi, Craig L.
    Langley, Richard G.
    Strober, Bruce E.
    Kaul, Martin
    Gu, Yihua
    Okun, Martin
    Papp, Kim
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (01) : 106 - 115
  • [8] Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
    Papp, Kim
    Reich, Kristian
    Leonardi, Craig L.
    Kircik, Leon
    Chimenti, Sergio
    Langley, Richard G. B.
    Hu, ChiaChi
    Stevens, Randall M.
    Day, Robert M.
    Gordon, Kenneth B.
    Korman, Neil J.
    Griffiths, Christopher E. M.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (01) : 37 - 49
  • [9] Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
    Paul, C.
    Cather, J.
    Gooderham, M.
    Poulin, Y.
    Mrowietz, U.
    Ferrandiz, C.
    Crowley, J.
    Hu, C.
    Stevens, R. M.
    Shah, K.
    Day, R. M.
    Girolomoni, G.
    Gottlieb, A. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (06) : 1387 - 1399
  • [10] Reich K., 2015, SUMM AC M AM AC DERM
12